Compare AstraZeneca plc (AZN) vs Bitdeer Technologies Group (BTDR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Bitdeer Technologies Group — how do they compare? AstraZeneca plc trades at $159.3 (market cap $246.15B), while Bitdeer Technologies Group trades at $9.65 (market cap $2.62B). The key difference: AstraZeneca plc is far larger — about 94× Bitdeer Technologies Group's market cap, and AstraZeneca plc pays a 2.01% dividend while Bitdeer Technologies Group pays none. Which is the better fit depends on your goals — on Pluang, investors hold AstraZeneca plc for 126 Days and Bitdeer Technologies Group for 16 Days on average.
| AZN | BTDR | |
|---|---|---|
Market Cap | $246.15B | $2.62B |
Volume | 2,058,882 | 5,882,825 |
Sector | Health | Technology |
52-Week High | $209.48 | $25.90 |
52-Week Low | $155.62 | $7.28 |
Typical Hold Time | 126 Days | 16 Days |
Enterprise Value | $273.42B | $4.07B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $159.20, showing modest daily gains of 0.26% amid bearish technical signals. The stock demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $2.63 exceeding expectations of $2.50. Revenue growth has accelerated from $44.4B in 2022 to $58.7B in 2025, with net income margin expanding to 17.4%. Recent developments include a $2 billion strategic investment in Summit Therapeutics to advance cancer drug combinations, highlighting ongoing R&D focus.
The outlook remains positive given analyst consensus price target of $186.67 (17% upside) and 49% buy ratings. Key risks include clinical trial outcomes for new drug combinations and pharmaceutical regulatory hurdles. Strong cash flow generation ($14.6B operating cash flow in 2025) supports continued dividend payments and strategic investments.
BTDR trades at $9.63, down 0.93% with bearish technical signals despite strong analyst support. The company shows mixed fundamentals with $620M revenue but negative net income margin of -28.14%. Recent news highlights significant AI cloud commitments exceeding $1.7B, driving investor optimism about future growth potential.
While analyst consensus remains strongly bullish with $20.50 price target, execution risks persist given negative profitability and cash flow challenges. The stock presents high-risk/high-reward opportunity as AI infrastructure expansion could drive substantial upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →
